login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
BIOAFFINITY TECHNOLOGIES INC (BIAF) Stock News
USA
- NASDAQ:BIAF -
US09076W1099
-
Common Stock
1.84
USD
-0.04 (-2.13%)
Last: 11/14/2025, 8:00:01 PM
1.7
USD
-0.14 (-7.61%)
After Hours:
11/14/2025, 8:00:01 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
BIAF Latest News, Press Relases and Analysis
All
Press Releases
19 hours ago - By: bioAffinity Technologies, Inc.
bioAffinity Technologies Reports Third Quarter 2025 Financial Results
10 days ago - By: bioAffinity Technologies, Inc.
bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume
18 days ago - By: bioAffinity Technologies, Inc.
bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases
2 months ago - By: Stocktwits
- Mentions:
VXF
bioAffinity Technologies Stock Surged A Whopping 56% Today – Here’s An Important Update
26 days ago - By: bioAffinity Technologies, Inc.
bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025
a month ago - By: Benzinga
Why Did bioAffinity Technologies' Stock Slip In After-Hours Trading After A Big Day Of Gains?
a month ago - By: Benzinga
- Mentions:
SBFM
ADAP
GNPX
HYPR
...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
a month ago - By: bioAffinity Technologies, Inc.
bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer
a month ago - By: bioAffinity Technologies, Inc.
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
a month ago - By: WallachBeth Capital LLC
WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
a month ago - By: bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
a month ago - By: WallachBeth Capital LLC
WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
a month ago - By: bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
a month ago - By: bioAffinity Technologies, Inc.
bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025
2 months ago - By: WallachBeth Capital LLC
WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m
2 months ago - By: bioAffinity Technologies, Inc.
bioAffinity Technologies Announces Closing of $4.8 Million Public Offering
2 months ago - By: WallachBeth Capital LLC
WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m
2 months ago - By: bioAffinity Technologies, Inc.
bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering
2 months ago - By: bioAffinity Technologies, Inc.
bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung
Please enable JavaScript to continue using this application.